Soligenix rises on data from co's Ebola and Marburg vaccine candidates

Soligenix

25/09/2023 14:18

** Soligenix Inc's shares  SNGX.O  rise 5% to $0.56
premarket
    ** Co says its vaccine candidates against Ebola and Marburg
viruses were found to be stable for at least two years when
stored at 40 degrees Celsius
    ** Adds it is the only protein-based vaccine platform shown
to protect against the two pathogens, which are from the
'filovirus' family of viruses 
    ** Both Ebola and Marburg are rare and deadly diseases that
have seen outbreaks primarily in some regions of Africa, where
power supply and distribution networks can be uncertain 
    ** Up to last close, stock had fallen 92% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))